This study is testing a new, emerging treatment for young adults (ages 18-26) with Posttraumatic Stress Disorder (PTSD). The treatment is combining the substance, MDMA, with up to three psychotherapy sessions, also known as MDMA-Assisted Therapy (MDMA-AT).
The main questions it aims to answer are:
* Is the treatment safe and feasible to administer?
* Does the treatment improve PTSD symptoms?
Participants will be asked to:
* Complete screening procedures, including a medical and psychiatric evaluation to ensure safe participation
* Attend up to three preparatory talk therapy sessions prior to the first MDMA-AT dosing session
* Attend three integration talk therapy sessions after each MDMA-AT dosing session
* Attend up to three total MDMA-AT dosing sessions
* Complete assessments from baseline to 38-weeks post-baseline
* Complete a fMRI scan at baseline and at 18-weeks post-treatment
* Complete self-report measures and ecological momentary assessments (EMAs) across the study period